Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer
The diversity and heterogeneity within high-grade serous ovarian cancer (HGSC), which is the most lethal gynecologic malignancy, is not well understood. Here, we perform comprehensive multi-platform omics analyses, including integrated analysis, and immune monitoring on primary and metastatic sites from highly clinically annotated HGSC samples based on a laparoscopic triage algorithm from patients who underwent complete gross resection (R0) or received neoadjuvant chemotherapy (NACT) with excellent or poor response. We identify significant distinct molecular abnormalities and cellular changes and immune cell repertoire alterations between the groups, including a higher rate of NF1 copy number loss, and reduced chromothripsis-like patterns, higher levels of strong-binding neoantigens, and a higher number of infiltrated T cells in the R0 versus the NACT groups.
Journal
Cell ReportsAuthors
Funding
Training of Academic Gynecologic OncologistsCancer Center Support GrantCore 1: Pathology CoreHarnessing the power of exosomes for non-coding RNA deliveryData GenerationIntegrated analysis of protein expression data from the Reverse Phase Protein Array (RPPA) platformThe University of Texas M. D. Anderson Cancer Center SPORE in Ovarian CancerTargeting Stromal Influences on Glutamine Addiction in Ovarian CancerTraining of Academic Surgical OncologistsMD Anderson Gynecologic SPORE for Uterine CancersIntegrative bioinformatics and functional characterization of oncogenic driver aberrations in cancerNational Institutes of Health FundingUniversity of Texas MD Anderson Cancer Center Funding